TM Owner Y-mAbs Therapeutics
Naxitamab Infusion 40mg/10ml Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Naxitamab Infusion, known by its FDA-approved brand name Danyelza, is a monoclonal antibody (naxitamab-gqgk) given by intravenous infusion in a hospital or specialist oncology setting.
- It is approved, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, in pediatric patients 1 year of age and older and in adult patients, who have shown at least a partial response to prior therapy.
- It was granted accelerated approval by the FDA based on tumour response rate, and continued approval may depend on further trials confirming clinical benefit.
- This is a rare, specialist-only cancer treatment, never self-administered, given as a course of infusions on set days of each treatment cycle in a facility equipped to manage severe reactions.
Side Effects
- Danyelza carries a boxed warning for two serious risks.
- First, serious infusion-related reactions, including cardiac arrest, anaphylaxis, low blood pressure, wheezing and stridor, occurred in almost all patients (94% to 100%) in clinical trials, with severe reactions in around a third to two-thirds; patients are premedicated and monitored closely during and after each infusion.
- Second, severe neurotoxicity can occur, including severe nerve pain, transverse myelitis and reversible posterior leukoencephalopathy syndrome (a brain condition causing headache, confusion, seizures or vision changes); pain of some degree affects almost all patients and is treated with pain medicine before and during infusions.
- Other very common effects include a fast heartbeat, vomiting, cough, nausea, diarrhoea, reduced appetite, high blood pressure, fatigue, skin rash or hives, fever, headache, and swelling.
- Tell the treating team immediately about chest pain, severe breathing difficulty, new severe pain, confusion, seizures or vision changes during or after an infusion.
Precautions & Warnings
- Danyelza must not be used in anyone with a history of severe hypersensitivity, including anaphylaxis, to naxitamab-gqgk.
- Because of the risk of serious infusion reactions and neurotoxicity described in the boxed warning, it is given only in a facility able to manage cardiac arrest, anaphylaxis and severe neurological events, with premedication - including neuropathic pain medicine started days beforehand and antihistamines, steroids and antiemetics before each infusion - and vital signs monitored throughout and after.
- It is for intravenous infusion only, never a rapid push or bolus injection, and is always given together with GM-CSF as part of the approved regimen.
- Use in pregnancy is not recommended, as animal data and the drug's mechanism suggest possible fetal harm; effective contraception is advised during treatment and for a period afterwards, and breastfeeding is not recommended during treatment.
- Blood counts and clinical status are monitored throughout each cycle.
- There is no home-storage or self-administration aspect to this medicine - it is prepared and given entirely by the hospital team.
Avoid Interactions
- Danyelza is always given together with GM-CSF (granulocyte-macrophage colony-stimulating factor) as part of its approved regimen, and the clinical team manages this combination directly.
- As a monoclonal antibody, it is not broken down by the liver enzymes that cause many small-molecule drug interactions, and no specific drug-drug interaction studies have been highlighted in its labelling; even so, tell the treating team about every other medicine, supplement and over-the-counter product being taken, since pain medicines, blood pressure medicines and other supportive treatments are commonly adjusted around each infusion because of the risk of infusion reactions and neuropathic pain.
- Medicines that lower blood pressure or affect heart rhythm should be discussed with the oncology team before treatment, given the risk of infusion-related cardiac and blood pressure changes.
- Live vaccines should generally be avoided during cancer treatment because of a weakened immune response; ask the treating team about vaccination timing.
- Danyelza must not be mixed with other medicines in the same infusion line.
References
Frequently Asked Questions
Naxitamab Infusion, brand name Danyelza, is a monoclonal antibody used with GM-CSF to treat relapsed or refractory high-risk neuroblastoma in bone or bone marrow. It is approved for patients aged 1 year and older, including adults, who responded at least partially to earlier treatment. It is given only in hospital.
Danyelza is given as an intravenous infusion on set days within each treatment cycle, alongside GM-CSF, in a hospital or specialist cancer unit. The first infusion runs over about 60 minutes and later ones over 30 to 60 minutes. You do not give it to yourself at home.
Danyelza carries a boxed warning for two serious risks: severe infusion reactions, including cardiac arrest and anaphylaxis, affecting nearly all patients, and severe neurotoxicity, including nerve pain and rare brain effects. You are premedicated and monitored closely during and after every infusion for this reason.
Very common Danyelza side effects include infusion reactions, pain, fast heartbeat, vomiting, cough, nausea, diarrhoea, reduced appetite, fatigue, rash and fever. Report chest pain, severe breathing trouble, confusion, seizures or new severe pain during or shortly after an infusion immediately.
You are premedicated with pain and reaction-prevention medicines, then given Danyelza by IV infusion together with GM-CSF, with close monitoring of your heart rate, blood pressure and breathing throughout and afterward, in a facility equipped to treat severe reactions immediately if they occur.
Yes. Danyelza is approved for pediatric patients aged 1 year and older as well as adults with relapsed or refractory high-risk neuroblastoma. It is not recommended in pregnancy, since it may harm an unborn baby, and effective contraception is advised during and after treatment.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
